ANI PHARMACEUTICALS, INC Acquisitions, Net of Cash Acquired
ANI PHARMACEUTICALS, INC (ANIP) reported Acquisitions, Net of Cash Acquired of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2025-11-07
- ANI PHARMACEUTICALS, INC payments to acquire businesses, net of cash acquired for the quarter ending 2023-12-31 was $0.00.
- ANI PHARMACEUTICALS, INC payments to acquire businesses, net of cash acquired for the quarter ending 2023-09-30 was $0.00.
- ANI PHARMACEUTICALS, INC payments to acquire businesses, net of cash acquired for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- ANI PHARMACEUTICALS, INC payments to acquire businesses, net of cash acquired for the quarter ending 2022-09-30 was $0.00.
- ANI PHARMACEUTICALS, INC payments to acquire businesses, net of cash acquired for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ANI PHARMACEUTICALS, INC payments to acquire businesses, net of cash acquired for fiscal 2022 was $33.00K, a 99.96% decline from fiscal 2021.
- ANI PHARMACEUTICALS, INC payments to acquire businesses, net of cash acquired for fiscal 2021 was $84.49M.
- ANI PHARMACEUTICALS, INC payments to acquire businesses, net of cash acquired for fiscal 2020 was $0.00.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-07 | |||
| 2024-09-30 | $393.08M 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-K · filed 2024-02-29 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $33.00K 10-K · filed 2024-02-29 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $33.00K 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $33.00K 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $84.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $84.49M derived: sum of 2 quarters · filed 2024-02-29 | $84.49M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-15 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 10-K · filed 2022-03-15 | ||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-06 | |||
| 2018-12-31 | -$600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $16.47M 10-K · filed 2021-03-11 | ||
| 2018-09-30 | $17.07M 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-06 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |